ClinicalTrials.gg
Not yet recruitingNCT07355959MOBISCANUpdated Jan 29, 2026

Clinical Study to Assess the Efficacy and Pressure Maintenance of MOBIDERM Autofit Versus Bandages in the Management of Breast Cancer Related Lymphedema (BCRL) in Night-time Maintenance Phase.

An interventional study of MOBIDERM Autofit Armsleeve and Self-bandages in Limb Lymphoedema, sponsored by Thuasne. Not yet recruiting at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Thuasne · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The aim of this cross-over, randomized study is to assess the efficacy and pressure maintenance of MOBIDERM Autofit versus bandages in the management of Breast Cancer Related Lymphedema (BCRL) in night-time maintenance phase.

Read the detailed description

In order to optimize treatment of lymphedema efficacy, THUASNE developed the standard Auto-Adjustable Armsleeve using the MOBIDERM technology, named MOBIDERM Autofit.

The device has already been evaluated in several clinical studies as an adjuvant treatment to daily compressive garment during night-time maintenance phase in women with Breast cancer related lymphedema.

The possibility to use this category of devices during both phases of lymphedema treatment has been reinforced recently by studies that showed a similar reduction in lymphedema volume with wraps versus conventional multilayer bandages [Ochalek et al., 2023,Borman et al., 2021].

The global objective of the MOBISCAN study is to reinforce the efficacy of MOBIDERM Autofit garment by assessing its efficacy and pressure maintenance versus bandages in the management of upper limb Lymphedema in night-time maintenance phase.

02

Conditions studied

  • Limb Lymphoedema

Keywords

  • Lymphedema of upper limb
  • Compression garments
  • Lymphedema management
03

In context

Lead sponsor

Thuasne is the lead sponsor of 21 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Unilateral upper limb lymphedema of stage I, II or III according to the criteria defined by the International Society of Lymphology, following breast cancer
  3. Patient in maintenance phase of lymphedema treatment
  4. Affected arm that fits with one of the standard sizes of the Auto- Adjustable MOBIDERM Autofit provided.
  5. Signed prior to any study-mandated procedure.

Exclusion criteria

Exclusion Criteria:

  1. Active cellulitis / Infectious dermo-hypodermatitis
  2. Lymphedema associated with active cancer needing acute chemotherapy
  3. Motor and sensitive neurological deficiency / psychiatric or addictive disorders
  4. Patients for whom compression is , such as untreated infections, skin irritation, thrombosis: presence of skin lesions on the sleeve placement
  5. Pregnant or breastfeeding patient
  6. Participation to any other clinical study which has an impact on the different endpoints
  7. Vulnerable patient, adults being the object of a legal protective measure or enable to express their consent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Other
    Group 1:

    Night-time MOBIDERM Autofit for the 1st month (1st phase) and self-bandages at night for the 2nd month (2nd phase).

    Device: MOBIDERM Autofit Armsleeve · Device: Self-bandages

  • Other
    Group 2:

    Self-bandages at night for the 1st month (1st phase) then Night-time MOBIDERM Autofit for the 2nd month (2nd phase).

    Device: MOBIDERM Autofit Armsleeve · Device: Self-bandages

Interventions

  • DeviceMOBIDERM Autofit Armsleeve

    The MOBIDERM Autofit Armsleeve will be worn by the patients at night for one month.

  • DeviceSelf-bandages

    Self-bandages will be worn by the patients at night for one month.

06

What researchers measure

Primary outcomes

  1. Volume excess variation

    The primary endpoint of this study is to compare the volume excess variation of the upper limb between both conditions: MOBIDERM Autofit and self-bandages after one month of treatment, using the SCANECA 3D scanner.

    Time frame: 2 months (Inclusion, first month and second month visit)

Secondary outcomes

  1. Evolution of affected upper limb volume:

    Evolution of affected upper limb volume between baseline and 1 month of treatment with MOBIDERM Autofit and self-bandages in patients with upper limb lymphedema.

    Time frame: 2 months (Inclusion, first month and second month visit)

  2. Device pressure:

    The level of pressure under the devices will be measured with Picopress during the 3 patient visits for each patient.

    Time frame: 2 months (Inclusion, first month and second month visit)

  3. Evolution of hand lymphedema:

    The volume of the hand related to healthy and to affected upper limb will be measured at baseline and the volume of the hand related to affected upper limb after one month of treatment with MOBIDERM Autofit and bandages with a digital measure device and/or tape measurement to check and compare the absence of migration of lymphedema towards the hand between both conditions.

    Time frame: 2 months (Inclusion, first month and second month visit)

  4. Comfort / Ease of use / satisfaction:

    A self-questionnaire will be completed by the patient at the end of the study when the patient tested each of the devices and is able to compare comfort, ease of use and satisfaction. A qualitative follow-up interview will be proposed to a dozen of patients at the end of the study to obtain their feed-back about their study treatments (overall experience, benefits of self-management, experience when putting on, taking off and adjusting the device).

    Time frame: 2 month visit

  5. Compliance:

    The patient will complete a diary during the study to report the compliance with each device at night (Wear/not wear, number of hours).

    Time frame: 2 months

  6. Patient's safety

    The Number and type of serious and non-serious Adverse Device Effects (ADE) with a focus on the cutaneous ADE will be collected during the study.

    Time frame: 2 months

07

Study locations

1 site
  • Ödemzentrum Bad Berleburg Klinik
    Bad Berleburg, 57319, Germany
08

References and documents

Publications

  • Cancer Information Sytem. https://www.wcrf.org/cancer-trends/worldwide-cancer-data/ (September 2023, date last accessed).

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Jul 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 21, 2026
StartEst.
Jan 15, 2026
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07355959
Lead sponsor
Thuasne
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Jan 15, 2026 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jan 29, 2026

Study contacts

Stéphanie Villet, Dr
Contact
stephanie.villet@thuasne.fr
+33647780429
Alyssia Marques
Contact
alyssia.marques@thuasne.fr
+33 6 48 22 64 56
Christina Lindemann, Physician
principal investigator · Ödemzentrum Bad Berleburg Klinik "Haus am Schloßpark" Hochstr. 7 D 57319 Bad Berleburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion